Marc Goodman

Stock Analyst at Leerink Partners

(2.59)
# 761
Out of 5,235 analysts
139
Total ratings
56.52%
Success rate
31.38%
Average return
40 Stocks
Name Action Price Target Current % Upside Ratings Updated
Relmada Therapeutics
Downgrades: Market Perform
10 1
0.48 108.33% 3 Dec 4, 2024
Biohaven
Maintains: Outperform
55 60
n/a n/a 6 Sep 23, 2024
LENZ Therapeutics
Initiates Coverage On: Outperform
32
27.07 18.21% 1 Apr 15, 2024
Amylyx Pharma
Downgrades: Market Perform
n/a
n/a n/a 4 Mar 11, 2024
Belite Bio
Initiates Coverage On: Outperform
25
58.79 -57.48% 1 Jul 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
1
n/a n/a 5 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
21.18 136.07% 1 Jan 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 23
0.53 4239.62% 4 Jan 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 20
10.71 86.74% 3 Jan 19, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 85
83.76 1.48% 6 Nov 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
15 1
n/a n/a 4 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
100 115
n/a n/a 4 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
270 310
153.14 102.43% 11 Oct 26, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
9 4
n/a n/a 4 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 12
n/a n/a 2 Aug 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 46
n/a n/a 4 Aug 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
170 270
n/a n/a 2 Aug 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 21
n/a n/a 5 Aug 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
200 210
122.69 71.16% 5 Aug 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
50 40
5.97 570.02% 5 Jul 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 10
2.93 241.3% 2 Jul 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
24 27
28.51 -5.3% 5 Apr 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
25
3.85 549.35% 1 Apr 26, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 70
83.24 -15.91% 3 Apr 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
10 2
n/a n/a 4 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 15
5.09 194.7% 2 Dec 21, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
37 32
n/a n/a 3 Dec 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
322 70
n/a n/a 3 May 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
200 220
n/a n/a 1 Feb 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
300 270
428.36 -36.97% 5 Mar 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
79 96
179.49 -46.52% 5 Nov 19, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
189 203
n/a n/a 5 Nov 19, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
72 0
n/a n/a 2 May 21, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Nov 13, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
6 7
n/a n/a 4 Nov 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
12 16
n/a n/a 2 Oct 30, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
72 67
101.02 -33.68% 3 Oct 30, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
19 15
n/a n/a 2 Oct 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
84 98
n/a n/a 3 Oct 5, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Mar 20, 2017